- Current report filing (8-K)
18 Febbraio 2011 - 10:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): February 14, 2011
SUNESIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51531
|
|
94-3295878
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
395 Oyster Point Boulevard, Suite 400
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650) 266-3500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain
Officers; Compensatory Arrangements of Certain Officers.
On February 14, 2011, our Board of Directors, or the Board,
approved our 2011 Bonus Program. The 2011 Bonus Program provides our executive officers and other eligible employees the opportunity to earn cash bonuses based on the level of achievement by us of certain corporate objectives, or the Corporate
Objectives, and by each participant of certain individual objectives, or the Individual Objectives, from January 1, 2011 through December 31, 2011. The terms of the 2011 Bonus Program are substantially consistent with the terms of our 2010
Bonus Program.
The Board has approved the Corporate Objectives and assigned a weighting to each objective. The Compensation
Committee of the Board, or the Committee, will set the Individual Objectives of our chief executive officer, as well as the Individual Objectives of the remaining executive officers based on the recommendations of the chief executive
officer. The Individual Objectives of non-executive participants will be set by each participants immediate supervisor.
Each eligible participant in the 2011 Bonus Program may receive a cash bonus in an amount up to a specified percentage of such participants annual base salary earned in 2011, or the Bonus Targets.
Under the 2011 Bonus Program, the Bonus Targets range from 30% to 50% of a participants 2011 base salary for vice president level employees and above. The Bonus Targets for each of our named executive officers is as follows:
|
|
|
|
|
|
|
Named Executive Officer
|
|
|
|
Bonus Target Percentage
|
|
Daniel N. Swisher, Jr.
President and Chief Executive Officer
|
|
|
|
|
50.0
|
%
|
Eric H. Bjerkholt
Senior Vice President, Corporate Development and Finance, Chief Financial Officer and Corporate Secretary
|
|
|
|
|
37.5
|
|
Steven B. Ketchum, Ph.D.
Senior Vice President, Research and Development
|
|
|
|
|
37.5
|
|
The Committee will
determine the degree to which the Corporate Objectives have been met after receiving the analysis and recommendations of management. Based on such determination, the Committee will adjust these Bonus Targets accordingly.
The Committee will also determine the level of achievement of the Individual Objectives by our chief executive officer based on its
evaluation of the chief executive officers achievements and by the remaining executive officers based on the recommendations of the chief executive officer.
There is no set formula for determining the amount of bonus earned under the 2011 Bonus Program based on the achievement of the Corporate and Individual Objectives. Rather, the Committee will exercise its
discretion in determining the amount of cash bonus actually earned. Payment under the 2011 Bonus Program is expected to occur in the first quarter of 2012. A participant must remain an employee through the payment date under the 2011 Bonus Program
to be eligible to earn a cash bonus.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
.
|
|
|
Exhibit No.
|
|
Description
|
10.1
|
|
Sunesis Pharmaceuticals, Inc. 2011 Bonus Program.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SUNESIS PHARMACEUTICALS, INC.
|
|
|
|
Dated: February 18, 2011
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Eric H. Bjerkholt
|
|
|
|
|
|
|
Eric H. Bjerkholt
|
|
|
|
|
|
|
Senior Vice President, Corporate Development and
Finance, Chief Financial Officer and Corporate Secretary
|
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
10.1
|
|
Sunesis Pharmaceuticals, Inc. 2011 Bonus Program.
|
Grafico Azioni Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ:SNSSD)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Sunesis Pharmaceuticals, Inc. (MM) (NASDAQ:SNSSD)
Storico
Da Giu 2023 a Giu 2024